Teja Kulkarni
@tkulkarni.bsky.social
#PulmCC Physician Scientist #uabmedicine| Director #UAB-ILD program #curePF|#HarvardChanSPH alum|Wife and Triplet Mom #womeninmedicine
The “why” behind every decision is the person in front of us. In this conversation, I joined the Leap Together podcast to discuss the real-world complexity for patients living with pulmonary fibrosis.
Listen here: lpcur.com/LeapTogether...
#LeapTogetherPodcast #ClinicalTrials #curePF
Listen here: lpcur.com/LeapTogether...
#LeapTogetherPodcast #ClinicalTrials #curePF
November 12, 2025 at 8:04 PM
The “why” behind every decision is the person in front of us. In this conversation, I joined the Leap Together podcast to discuss the real-world complexity for patients living with pulmonary fibrosis.
Listen here: lpcur.com/LeapTogether...
#LeapTogetherPodcast #ClinicalTrials #curePF
Listen here: lpcur.com/LeapTogether...
#LeapTogetherPodcast #ClinicalTrials #curePF
Reposted by Teja Kulkarni
The Impact of Pulmonary Fibrosis on Sex and Sexual Function - A Multinational Mixed Methods Study
Just out in ERJ and led by Dr. Na'ama Avitzur
A 🧵👇
(key take-away 👉 sex matters to patients with PF and their disease impacts this)
#OpenAccess #CurePF #CureIPF
publications.ersnet.org/content/erj/...
Just out in ERJ and led by Dr. Na'ama Avitzur
A 🧵👇
(key take-away 👉 sex matters to patients with PF and their disease impacts this)
#OpenAccess #CurePF #CureIPF
publications.ersnet.org/content/erj/...
October 14, 2025 at 1:59 AM
The Impact of Pulmonary Fibrosis on Sex and Sexual Function - A Multinational Mixed Methods Study
Just out in ERJ and led by Dr. Na'ama Avitzur
A 🧵👇
(key take-away 👉 sex matters to patients with PF and their disease impacts this)
#OpenAccess #CurePF #CureIPF
publications.ersnet.org/content/erj/...
Just out in ERJ and led by Dr. Na'ama Avitzur
A 🧵👇
(key take-away 👉 sex matters to patients with PF and their disease impacts this)
#OpenAccess #CurePF #CureIPF
publications.ersnet.org/content/erj/...
The approval of Nerandomilast marks a pivotal step forward in IPF care. For patients living with IPF, this offers long awaited hope and this milestone underscores the collective efforts of multiple stakeholders who never stopped pushing for better therapeutic options for IPF.
Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade.
Congratulations to all our patients & yes, better drugs are on the way!!
Great day for the #CureIPF community!!
#ScienceMatters
www.fda.gov/drugs/news-e...
Congratulations to all our patients & yes, better drugs are on the way!!
Great day for the #CureIPF community!!
#ScienceMatters
www.fda.gov/drugs/news-e...
FDA approves drug to treat idiopathic pulmonary fibrosis
First new treatment in more than a decade for rare lung condition
www.fda.gov
October 9, 2025 at 10:00 PM
The approval of Nerandomilast marks a pivotal step forward in IPF care. For patients living with IPF, this offers long awaited hope and this milestone underscores the collective efforts of multiple stakeholders who never stopped pushing for better therapeutic options for IPF.
Reposted by Teja Kulkarni
Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade.
Congratulations to all our patients & yes, better drugs are on the way!!
Great day for the #CureIPF community!!
#ScienceMatters
www.fda.gov/drugs/news-e...
Congratulations to all our patients & yes, better drugs are on the way!!
Great day for the #CureIPF community!!
#ScienceMatters
www.fda.gov/drugs/news-e...
FDA approves drug to treat idiopathic pulmonary fibrosis
First new treatment in more than a decade for rare lung condition
www.fda.gov
October 8, 2025 at 7:32 PM
Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade.
Congratulations to all our patients & yes, better drugs are on the way!!
Great day for the #CureIPF community!!
#ScienceMatters
www.fda.gov/drugs/news-e...
Congratulations to all our patients & yes, better drugs are on the way!!
Great day for the #CureIPF community!!
#ScienceMatters
www.fda.gov/drugs/news-e...
Reposted by Teja Kulkarni
TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁
Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD
@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
www.theglobeandmail.com/investing/ma...
Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD
@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
www.theglobeandmail.com/investing/ma...
September 2, 2025 at 2:56 PM
TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁
Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD
@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
www.theglobeandmail.com/investing/ma...
Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD
@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
www.theglobeandmail.com/investing/ma...
Reposted by Teja Kulkarni
Heading to #ATS2025 🫁?
Wondering about the Clinical Problems assembly content?
📻 Check out this podcast where we break it down for you 👇😁
@ats-clinicalprobs.bsky.social
@atsearlycareer.bsky.social
Wondering about the Clinical Problems assembly content?
📻 Check out this podcast where we break it down for you 👇😁
@ats-clinicalprobs.bsky.social
@atsearlycareer.bsky.social
#ATS2025 starts THIS WEEK! Prepare with our 🌟NEW PODCAST🌟 the CP Assembly's roadmap 🗺️ to #ATS2025! Join host Dr. @kerrijohannson.bsky.social as she breaks down must-see sessions at #ATS2025 with Drs. Kerri Aaronson, Justin Oldham, and Surya Bhatt
youtu.be/5iVM9_yDXsE
youtu.be/5iVM9_yDXsE
Clinical Problems Assembly Roadmap to ATS 2025
Drs. Kerri Aronson, Surya Bhatt, and Justin Oldham join Dr. Kerri Johannson to give CP Assembly members a rundown of to our sessions ATS 2025 conference in S...
youtu.be
May 12, 2025 at 9:17 PM
Heading to #ATS2025 🫁?
Wondering about the Clinical Problems assembly content?
📻 Check out this podcast where we break it down for you 👇😁
@ats-clinicalprobs.bsky.social
@atsearlycareer.bsky.social
Wondering about the Clinical Problems assembly content?
📻 Check out this podcast where we break it down for you 👇😁
@ats-clinicalprobs.bsky.social
@atsearlycareer.bsky.social
Amplification of patients voices is key to personalized care. Excited about our recent study highlighting the disease burden and critical gaps as we move towards patient focused management for individuals living with IPF #curePF bmcpulmmed.biomedcentral.com/articles/10....
Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study - BMC Pulmonary Medicine
Background The antifibrotic therapies, pirfenidone and nintedanib, have been approved since 2014 for idiopathic pulmonary fibrosis (IPF), but in the United States only a quarter of people living with ...
bmcpulmmed.biomedcentral.com
May 9, 2025 at 12:29 PM
Amplification of patients voices is key to personalized care. Excited about our recent study highlighting the disease burden and critical gaps as we move towards patient focused management for individuals living with IPF #curePF bmcpulmmed.biomedcentral.com/articles/10....
Reposted by Teja Kulkarni
Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Fibrosis: cross-organ biology and pathways to development of innovative drugs - Nature Reviews Drug Discovery
Fibrosis is a key characteristic of a range of chronic diseases that has been challenging to target with drugs. This Review highlights core pathways active in fibrotic conditions across organs, as wel...
www.nature.com
March 22, 2025 at 11:11 AM
Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Teja Kulkarni
Exactly. Think about it - what if this drug improves FVC - what would the patients’ risk tolerance be?
March 3, 2025 at 9:27 PM
Exactly. Think about it - what if this drug improves FVC - what would the patients’ risk tolerance be?
Reposted by Teja Kulkarni
The ATS CP apprenticeship program is a great way to get involved with the assembly!
Get more info and apply here:
tinyurl.com/439v6xam
Make sure to select the clinical problems assembly and apply before January 24!⏰
#pulmsky #medsky
Get more info and apply here:
tinyurl.com/439v6xam
Make sure to select the clinical problems assembly and apply before January 24!⏰
#pulmsky #medsky
American Thoracic Society | ATS Apprenticeship Program
The American Thoracic Society is the world's leading medical society dedicated to accelerating the advancement of global respiratory health through…
tinyurl.com
January 16, 2025 at 9:38 PM
The ATS CP apprenticeship program is a great way to get involved with the assembly!
Get more info and apply here:
tinyurl.com/439v6xam
Make sure to select the clinical problems assembly and apply before January 24!⏰
#pulmsky #medsky
Get more info and apply here:
tinyurl.com/439v6xam
Make sure to select the clinical problems assembly and apply before January 24!⏰
#pulmsky #medsky
Reposted by Teja Kulkarni
🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟
Just out in @atsblueeditor.bsky.social 🫁
www.atsjournals.org/doi/abs/10.1...
State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions
Just out in @atsblueeditor.bsky.social 🫁
www.atsjournals.org/doi/abs/10.1...
State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions
January 4, 2025 at 6:53 PM
🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟
Just out in @atsblueeditor.bsky.social 🫁
www.atsjournals.org/doi/abs/10.1...
State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions
Just out in @atsblueeditor.bsky.social 🫁
www.atsjournals.org/doi/abs/10.1...
State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions
Reposted by Teja Kulkarni
Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
December 21, 2024 at 6:52 AM
Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
An excellent 🧵on potential application of Mendelian randomization towards target identification and therapeutic development #cureIPF #REMAP-ILD
Using Mendelian Randomisation to identify causal associations in #IPF a 🧵
December 5, 2024 at 11:37 PM
An excellent 🧵on potential application of Mendelian randomization towards target identification and therapeutic development #cureIPF #REMAP-ILD
Reposted by Teja Kulkarni
There’s still time to submit session ideas for #CHEST2025! Don't miss your chance to speak! Need help? Just ask me! info.chestnet.org/chest-call-f...
December 3, 2024 at 7:14 PM
There’s still time to submit session ideas for #CHEST2025! Don't miss your chance to speak! Need help? Just ask me! info.chestnet.org/chest-call-f...
Among other factors, this real-world study underscores the importance of addressing mental health in patients with IPF #curePF
In idiopathic pulmonary fibrosis (IPF), lack of persistence in following antifibrotic therapy was linked to patient variables that included depression, lower DLCO, higher all-cause mortality, and worse transplant-free survival: Annals of the ATS.
www.pulmonologyadvisor.com/news/ipf-ant...
www.pulmonologyadvisor.com/news/ipf-ant...
IPF Antifibrotic Therapy Discontinuation Linked to Depression, Lower DLCO
In IPF, antifibrotic therapy discontinuation was linked to patient variables that included depression, lower DLCO, and higher all-cause mortality.
www.pulmonologyadvisor.com
November 21, 2024 at 5:46 PM
Among other factors, this real-world study underscores the importance of addressing mental health in patients with IPF #curePF
Reposted by Teja Kulkarni
Continued awareness and identification of IPF needs to continue.
In idiopathic pulmonary fibrosis (IPF), lack of persistence in following antifibrotic therapy was linked to patient variables that included depression, lower DLCO, higher all-cause mortality, and worse transplant-free survival: Annals of the ATS.
www.pulmonologyadvisor.com/news/ipf-ant...
www.pulmonologyadvisor.com/news/ipf-ant...
IPF Antifibrotic Therapy Discontinuation Linked to Depression, Lower DLCO
In IPF, antifibrotic therapy discontinuation was linked to patient variables that included depression, lower DLCO, and higher all-cause mortality.
www.pulmonologyadvisor.com
November 21, 2024 at 5:37 PM
Continued awareness and identification of IPF needs to continue.
Reposted by Teja Kulkarni
So excited to hear what @kerrijohannson.bsky.social has to tell us about the impact of our environment on the development of pulmonary fibrosis! The whole lecture will be available on-line via the MTW website: www.imperial.ac.uk/mtw-centre-f...
November 19, 2024 at 4:08 PM
So excited to hear what @kerrijohannson.bsky.social has to tell us about the impact of our environment on the development of pulmonary fibrosis! The whole lecture will be available on-line via the MTW website: www.imperial.ac.uk/mtw-centre-f...
Reposted by Teja Kulkarni
Really cool! our “Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis” made it to cover of the American Journal of Respiratory & Critical Care Medicine. Kudos to soon to be #DoubleDoc Amy Zhao & crew!! #BestStudents www.atsjournals.org/doi/full/10....
November 16, 2024 at 1:33 AM
Really cool! our “Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis” made it to cover of the American Journal of Respiratory & Critical Care Medicine. Kudos to soon to be #DoubleDoc Amy Zhao & crew!! #BestStudents www.atsjournals.org/doi/full/10....
Reposted by Teja Kulkarni
Made my first pilgrimage to ACCP in Glenview, IL this week. Thanks #Chest for the hospitality! @tkulkarni.bsky.social
November 13, 2024 at 11:17 PM
Made my first pilgrimage to ACCP in Glenview, IL this week. Thanks #Chest for the hospitality! @tkulkarni.bsky.social